CIK 0001710072 · Large accelerated filer
Edgewise Therapeutics, Inc.
Sign in to watch- Ticker
- EWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821725586
- Phone
- 720-262-7002
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $201,787
- in 1 filing
Net −$201,787. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-08 | MOORE JOHN R General Counsel | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,813 | 101,191 | ||
| 2024-02-08 | Derakhshan Behrad Chief Business Officer | Option exercise 10b5-1 | +4,600 | $1.93 | $9K | 11,620 |
| 2024-02-08 | Derakhshan Behrad Chief Business Officer | Sale 10b5-1 | −4,600 | $20.01 | $92K | 7,020 |
| 2024-02-08 | Derakhshan Behrad Chief Business Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,600 | 149,817 | ||
| 2024-02-07 | MOORE JOHN R General Counsel | Option exercise 10b5-1 | +17,993 | $1.93 | $35K | 17,993 |
| 2024-02-07 | MOORE JOHN R General Counsel | Sale 10b5-1 | −17,993 | $20.00 | $360K | 0 |
| 2024-02-07 | MOORE JOHN R General Counsel | Option exercise · Stock Option (Right to Buy) 10b5-1 | −17,993 | 105,004 | ||
| 2024-02-07 | Derakhshan Behrad Chief Business Officer | Option exercise 10b5-1 | +600 | $1.93 | $1K | 7,620 |
| 2024-02-07 | Derakhshan Behrad Chief Business Officer | Sale 10b5-1 | −600 | $20.00 | $12K | 7,020 |
| 2024-02-07 | Derakhshan Behrad Chief Business Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −600 | 154,417 | ||
| 2024-01-23 | Carruthers R Michael Chief Financial Officer | Option exercise 10b5-1 | +90,000 | $1.93 | $174K | 119,024 |
| 2024-01-23 | Carruthers R Michael Chief Financial Officer | Sale 10b5-1 | −90,000 | $15.78 | $1.4M | 29,024 |
| 2024-01-23 | Carruthers R Michael Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −90,000 | 137,058 | ||
| 2024-01-23 | Thompson Peter A. Director | Purchase | +454,545 | $11.00 | $5.0M | 14,436,497 |
| 2024-01-23 | ORBIMED ADVISORS LLC Director | Purchase | +454,545 | $11.00 | $5.0M | 14,436,497 |
| 2023-12-27 | MOORE JOHN R General Counsel | Sale | −8,497 | $10.50 | $89K | 0 |
| 2023-12-26 | Fox Jonathan C Director | Purchase | +10,857 | $9.30 | $101K | 10,857 |
| 2023-12-26 | Russell Alan J Chief Scientific Officer | Sale | −172,585 | $9.33 | $1.6M | 3,606 |
| 2023-08-17 | Derakhshan Behrad Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +220,000 | 220,000 | ||
| 2023-08-17 | MOORE JOHN R General Counsel | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 |
Page 15 of 26 · 509 trades